JP2024529839A5 - - Google Patents

Info

Publication number
JP2024529839A5
JP2024529839A5 JP2023580379A JP2023580379A JP2024529839A5 JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5 JP 2023580379 A JP2023580379 A JP 2023580379A JP 2023580379 A JP2023580379 A JP 2023580379A JP 2024529839 A5 JP2024529839 A5 JP 2024529839A5
Authority
JP
Japan
Prior art keywords
caution
membered
alkyl
heterocycloalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/035306 external-priority patent/WO2023278438A1/en
Publication of JP2024529839A publication Critical patent/JP2024529839A/ja
Publication of JP2024529839A5 publication Critical patent/JP2024529839A5/ja
Pending legal-status Critical Current

Links

JP2023580379A 2021-06-29 2022-06-28 Ｎｌｒｐ３モジュレーター Pending JP2024529839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163216446P 2021-06-29 2021-06-29
US63/216,446 2021-06-29
US202263320155P 2022-03-15 2022-03-15
US63/320,155 2022-03-15
PCT/US2022/035306 WO2023278438A1 (en) 2021-06-29 2022-06-28 Nlrp3 modulators

Publications (2)

Publication Number Publication Date
JP2024529839A JP2024529839A (ja) 2024-08-14
JP2024529839A5 true JP2024529839A5 (https=) 2025-06-30

Family

ID=84692056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580379A Pending JP2024529839A (ja) 2021-06-29 2022-06-28 Ｎｌｒｐ３モジュレーター

Country Status (5)

Country Link
US (1) US20240327413A1 (https=)
EP (1) EP4362946A4 (https=)
JP (1) JP2024529839A (https=)
TW (1) TW202319054A (https=)
WO (1) WO2023278438A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
LT4363406T (lt) 2021-07-02 2025-12-29 Astrazeneca Ab Nlrp3 inflamasomų inhibitoriai
TW202319055A (zh) 2021-07-21 2023-05-16 日商安斯泰來製藥股份有限公司 縮環噠嗪（ｐｙｒｉｄａｚｉｎｅ）化合物
CN118302417A (zh) * 2021-08-25 2024-07-05 Ptc医疗公司 Nlrp3抑制剂
CR20240093A (es) 2021-08-25 2024-05-23 Ptc Therapeutics Inc Inhibidores de NLRP3
WO2023051761A1 (zh) * 2021-09-30 2023-04-06 成都奥睿药业有限公司 一类取代杂芳酞嗪衍生物的药学用途及其制备方法
WO2023066377A1 (zh) 2021-10-22 2023-04-27 索智生物科技（浙江）有限公司 一种含氮化合物、其制备方法及应用
WO2023088856A1 (en) * 2021-11-17 2023-05-25 F. Hoffmann-La Roche Ag Heterocyclic nlrp3 inhibitors
JP2025511199A (ja) * 2022-03-31 2025-04-15 ハンチョウ ハイライトゥル ファーマシューティカル カンパニー リミテッド Ｎｌｒｐ３インフラマソーム阻害剤
US20260015357A1 (en) * 2022-07-01 2026-01-15 Neumora Therapeutics, Inc. Modulators of nlrp3 inflammasome and related products and methods
JP2025524640A (ja) * 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN120379995A (zh) * 2022-12-27 2025-07-25 正大天晴药业集团股份有限公司 一种哒嗪稠芳环化合物及其用途
CN120569372A (zh) * 2023-01-24 2025-08-29 第一三共株式会社 经取代的苯化合物
KR20250151413A (ko) * 2023-01-31 2025-10-21 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 이미다조[1,2-d][1,2,4]트라이아진
KR20250134147A (ko) 2023-01-31 2025-09-09 얀센 파마슈티카 엔브이 NLRP3 억제제로서의 피롤로[1,2-d][1,2,4]트리아진 및 피라졸로[1,5-d] [1,2,4]트리아진
WO2024160694A1 (en) * 2023-01-31 2024-08-08 Janssen Pharmaceutica Nv [1,2,4]TRIAZOLO[4,3-a]PYRIDINES AND [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS NLRP3 INHIBITORS
TW202448892A (zh) * 2023-04-17 2024-12-16 大陸商上海拓界生物醫藥科技有限公司 稠合噠嗪類衍生物及其用途
KR20260027946A (ko) 2023-06-02 2026-03-03 머크 샤프 앤드 돔 엘엘씨 Nod-유사 수용체 단백질 3의 억제제로서 유용한 5,6 불포화 비시클릭 헤테로사이클
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2026057747A1 (en) 2024-09-11 2026-03-19 Ac Immune Sa Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds
WO2026082103A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于预防和/或治疗与体重增加相关的疾病或病症的用途
WO2026082092A1 (zh) * 2024-10-16 2026-04-23 青岛博森泰科技有限公司 一种nlrp3抑制剂用于治疗炎症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919957D0 (en) * 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
FR2868780B1 (fr) * 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
WO2006004589A2 (en) * 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
WO2018221433A1 (ja) * 2017-05-29 2018-12-06 第一三共株式会社 ヘテロアリールアミン誘導体
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
JP7595642B2 (ja) * 2019-07-17 2024-12-06 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
CN118302417A (zh) * 2021-08-25 2024-07-05 Ptc医疗公司 Nlrp3抑制剂

Similar Documents

Publication Publication Date Title
JP2024529839A5 (https=)
JP2025509697A5 (https=)
JP2022541254A5 (https=)
JP6506836B2 (ja) Ｂ型肝炎ウイルス感染症の処置および予防のための新規ピリダゾンおよびトリアジノン
JP2020528889A5 (https=)
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
JP2011513367A5 (https=)
JP2009531292A5 (https=)
JP2025509281A5 (https=)
HRP20120900T1 (hr) Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu
JP2009524691A5 (https=)
JP2021523200A5 (https=)
JP2019519598A5 (https=)
JP2022552445A5 (https=)
JP2017531016A5 (https=)
JP2023518044A5 (https=)
JP5539978B2 (ja) チアゾピリミジノンおよびその使用
JP2000516932A (ja) 新規のベンゾフラン―４―カルボキサミド
JP2022519696A5 (https=)
JP7604018B2 (ja) 化合物、その薬学的に許容される塩又は立体異性体、及びその使用
EA018995B1 (ru) Производные карбаматов алкилтиазолов, их получение и их применение в терапии
JP2005539026A5 (https=)
JP2021528405A5 (https=)
RU2007102576A (ru) Новые индаэолкарбоксамиды и их применение
JP2023530708A5 (https=)